Biomea Fusion (BMEA) to Release Earnings on Wednesday

Biomea Fusion (NASDAQ:BMEA - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Biomea Fusion Stock Performance

Shares of NASDAQ BMEA traded down $0.17 during mid-day trading on Wednesday, reaching $2.52. 737,779 shares of the company's stock were exchanged, compared to its average volume of 921,108. The company's 50-day moving average is $3.38 and its 200-day moving average is $6.07. The firm has a market capitalization of $91.32 million, a price-to-earnings ratio of -0.63 and a beta of -0.26. Biomea Fusion has a 52-week low of $2.35 and a 52-week high of $16.29.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $16.00 target price on shares of Biomea Fusion in a research note on Wednesday, March 19th. Oppenheimer set a $10.00 price objective on shares of Biomea Fusion in a research report on Monday. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Biomea Fusion in a report on Monday. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $24.64.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.